Core Insights - Firefly Neuroscience, Inc. has successfully raised $8,824,710 through the exercise of warrants, significantly enhancing its cash position and extending its cash runway into mid-2026 [1][3] - The funds will be allocated for general working capital and to support the strategic initiative of developing a foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology [2][3] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, utilizing its FDA-cleared BNA™ technology [3][4] - The BNA™ technology is based on a proprietary database of over 17,000 patients' high-definition longitudinal electroencephalograms (EEGs), enabling comprehensive insights into brain function for better diagnosis and treatment of mental and cognitive disorders [4] Strategic Initiatives - The company is launching BNA™ commercially, targeting pharmaceutical companies involved in drug research and clinical trials, as well as medical practitioners for clinical applications [3][4]
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million